Sizheng Zhao

2 weeks ago | onlinelibrary.wiley.com | Sizheng Zhao |Gema Hernández |Uazman Alam

JAK inhibitors (JAKi) are highly effective for treating atopic dermatitis (AD). However, concerns about cardiovascular and cancer risk persist, as their elevated risk was observed in the ORAL surveillance trial of rheumatoid arthritis (RA) [1]. While the RA and AD populations likely differ, AD is independently associated with an increased risk of cardiovascular disease and cancer compared with the general population [2, 3].

Jul 8, 2024 | acrjournals.onlinelibrary.wiley.com | Sizheng Zhao |Kimme Hyrich |Zenas Yiu |Anne Barton

INTRODUCTION Inhibitors of the interleukin 13 (IL-13) pathway, such as dupilumab (dual interleukin 4 [IL-4]/IL-13 inhibitor), tralokinumab, and lebrikizumab (pure IL-13 inhibitors), were developed to treat atopic diseases including atopic dermatitis, chronic rhinosinusitis, and asthma.1-4 Musculoskeletal adverse events resembling seronegative spondyloarthritis have been reported after dupilumab initiation, but evidence is limited to case series and spontaneous pharmacovigilance with uncertain...

Aug 22, 2023 | dialnet.unirioja.es | Sizheng Zhao |Zenas Yiu |Anne Barton |John Bowes

Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization StudyAutores: Sizheng Steven Zhao, Zenas Z.N. Yiu, Anne Barton, John BowesLocalización: JAMA Dermatology, ISSN 2168-6068, Vol. 159, Nº. 3, 2023, págs. 275-280Idioma: inglésEnlacesTexto completoResumenImportance Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying properties.